IMV Inc. (IMV) Reports Q1 Loss of $0.10

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. CRWD
2. REGN
3. LITE
4. AAPL
5. ABBV
6. MRVL
7. CL
8. LYB
9. TFII
10. RXRX

Go back to IMV Inc. (IMV) Reports Q1 Loss of $0.10

IMV Inc. Announces First Quarter 2021 Financial and Operational Results and Expansion of its Clinical Pipeline

May 12, 2021 7:05 AM EDT

Phase 2B study in r/r DLBCL to begin in Q2 of this year

New investigator-initiated study of maveropepimut-S in breast cancer to be initiated this summer

First in human dual-targeted immunotherapy (DPX-SurMAGE) study in bladder cancer later in the year

Two recognized senior leaders joined Board of Directors

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)-- IMV Inc. (the Company or IMV) (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced its financial and... More